Redefining the unit economics of drug discovery for better patient outcomes
With an estimated 10⁶⁰ possible drug-like molecules, the chemical space is unimaginably large. And yet, most programs still start from the same limited chemical matter.
Traditional drug discovery begins from known compounds (screening hits, literature scaffolds, familiar chemical matter…) and then commits to long, costly optimization cycles, over-investing in the exploitation of limited starting points.
Variational AI believes in a different approach. Using generative AI, we design novel, synthesizable small molecules optimized across potency, selectivity, ADMET, and synthetic feasibility, giving R&D teams higher-quality leads to initiate their discovery programs.
Better starting points mean fewer costly iterations, faster timelines, and a higher probability of success, so more programs reach the patients who need them.
From target product profile to synthesis-ready leads in weeks
Enki™ generates novel lead-like structures to meet selectivity, potency, toxicity, and pharmacokinetic program goals.
1. Define the preclinical target product profile (TPP)
Specify the On/Off-targets and physico-chemical properties of the molecules as input for Enki™ generative AI.
2. Enki™ generates compounds
Enki™ generates novel and diverse structures that meet the defined TPP.
3. Make your selection
Pick compounds you want to synthesize and test. Enki™ can also perform hyper-efficient lead optimization while constrained to a defined scaffold.
Built for early-stage drug discovery
Enki™ is purpose-built for the earliest stages of small molecule drug discovery — generating first- and best-in-class compounds for 873 pre-trained drug targets spanning kinases, GPCRs, proteases, oxidoreductases, hydrolases, ion channels, and other key target classes.
Generative AI, not screening
Enki™ generates novel molecular structures de novo — moving beyond fixed screening libraries to explore uncharted regions of chemical space.
Multiparameter optimization
Enki™ simultaneously optimizes across 50+ parameters — potency, selectivity, toxicity, ADMET, PK, synthetic accessibility, and more…
The team behind Enki™
At Variational AI, we bring together machine learning researchers, chemists, and biotech professionals united by one mission: transforming early drug discovery with generative AI. Our cross-disciplinary team is always looking for new talents to push the boundaries of science and technology alongside us.
In the Press
Latest News
Variational AI Named “Gamechanger – AI” at BC Tech’s 2026 Technology Impact Awards
Variational AI is proud to announce that it has been named the winner of the Gamechanger – AI award at the BC Tech Association’s 2026 Technology Impact Awards (TIAs) Read More about Variational AI Named “Gamechanger – AI” at BC Tech’s 2026 Technology Impact Awards
Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US$1 million
How Rakovina Therapeutics designed a novel, brain-penetrant ATR inhibitor with Enki™: one design cycle to four IP-clear lead series, five optimization cycles to sub-nanomolar potency, 122 compounds, about two years,… Read More about Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US class=”wp-block-post-excerpt__more-link” href=”https://variational.ai/news/use-case/case-study-brain-penetrant-atr-inhibitor-kt-5000/” million
SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
Variational AI has entered a research collaboration with SK Life Science Labs, the U.S. discovery research subsidiary of SK Biopharmaceuticals. Variational AI will use its Enki™ generative AI platform to… Read More about SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Vancouver-based 3C Therapeutics to apply Variational AI’s Enki™ platform to ligand design for proprietary TriCore DAC platform under Innovate BC’s Integrated Marketplace program Read More about 3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Upcoming Events
CologneVariational AI at BIO-Europe 2026
Variational AI will participate in BIO-Europe 2026, one of the world’s leading partnering conferences for the biotechnology and pharmaceutical industries. The event brings together biotech companies, pharmaceutical firms, investors, and technology innovators from across the global life sciences ecosystem to explore partnerships, licensing opportunities, and new approaches to advancing therapeutic development. Meet the Variational AI…
